Effect duration of the initial course of peroneal electrical Transcutaneous NeuroModulation in patients with overactive bladder.

Autor: Rejchrt M; Department of Urology, 2nd Faculty of Medicine of Charles University and Motol University Hospital, Prague, Czech Republic.; Urological Office, Poliklinika RAVAK, Příbram, Czech Republic., Krhut J; Department of Urology, University Hospital, Ostrava, Czech Republic. jan.krhut@fno.cz.; Department of Surgical Studies, Faculty of Medicine, Ostrava University, Ostrava, Czech Republic. jan.krhut@fno.cz., Gärtner M; Gynuro s.r.o., Ostrava, Czech Republic., Blok BFM; Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands., Zvara P; Biomedical Laboratory and Research Unit of Urology, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.; Department of Urology, Odense University Hospital, Odense, Denmark.
Jazyk: angličtina
Zdroj: World journal of urology [World J Urol] 2023 Jun; Vol. 41 (6), pp. 1629-1634. Date of Electronic Publication: 2023 Apr 07.
DOI: 10.1007/s00345-023-04394-z
Abstrakt: Purpose: The aim of this prospective 12-month follow-up study is to evaluate the persistence of the treatment effect achieved during the initial course of peroneal electrical Transcutaneous NeuroModulation (peroneal eTNM ® ) in patients with overactive bladder (OAB).
Methods: This study enrolled 21 female patients who participated in two previous clinical studies designed to assess the efficacy and safety of peroneal eTNM ® . The patients were left without subsequent OAB treatment and were invited to attend regular follow-up visits every 3 months. The patient's request for additional treatment was considered an indicator of the withdrawal of the treatment effect of the initial course of peroneal eTNM ® . The primary objective was the proportion of patients with persisting treatment effect at follow-up visit 12 months after initial course of peroneal eTNM ® . Descriptive statistics are presented using median, correlation analyses were computed using a nonparametric Spearman correlation.
Results: The proportion of patients with persistent therapeutic effect of the initial course of peroneal eTNM ® was 76%, 76%, 62% and 48% at 3, 6, 9 and 12 months, respectively. There was a significant correlation between patient reported outcomes and the number of severe urgency episodes with or without urgency incontinence as reported by patients at each follow-up visit (p = 0.0017).
Conclusion: The treatment effect achieved during the initial phase of peroneal eTNM ® persists for at least 12 months in 48% of patients. It is likely that the duration of effects is dependent on the length of the initial therapy.
(© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: